Compare Garmin Ltd. (GRMN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs State Street SPDR S&P Biotech ETF — how do they compare? Garmin Ltd. trades at $268.19 (market cap $51.77B), while State Street SPDR S&P Biotech ETF trades at $154.12 (market cap $10.11B). The key difference: Garmin Ltd. is far larger — about 5.1× State Street SPDR S&P Biotech ETF's market cap, and Garmin Ltd. pays a 1.56% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Garmin Ltd. for 83 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| GRMN | XBI | |
|---|---|---|
Market Cap | $51.77B | $10.11B |
Volume | 961,398 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $313.16 | $169.55 |
52-Week Low | $187.10 | $104.99 |
Typical Hold Time | 83 Days | 37 Days |
Enterprise Value | $49.28B | — |
Dividend Yield | 1.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $276.16, down 1.09% on the day, with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, revenue growth from $4.9B in 2022 to $7.25B in 2025, and robust profitability margins. Recent news highlights product innovation and industry awards, reinforcing its market position.
The outlook is supported by solid financial health and analyst consensus pointing to upside, but risks include competitive pressures and market volatility. The stock presents a growth opportunity driven by execution, though investor caution is warranted near-term given technical weakness and macroeconomic uncertainties.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
